Analyst firms · Morgan Stanley · IOBT
Morgan Stanley IOBT price target and rating history
IO Biotech Inc. (IOBT) · Health Care
Morgan Stanley rates IO Biotech Inc. (IOBT) Underweight with a $0.36 price target, as of its latest action on Jan 8, 2026. It has published 3 rating actions on IOBT since November 2021, including 0 upgrades and 2 downgrades.
- Current rating
- Underweight
- Price target
- $0.36
- Median target, all firms
- Too few
- Actions on IOBT
- 3
Morgan Stanley price target on IOBT
Every Morgan Stanley rating on IOBT
- Jan 8, 2026
- Sep 30, 2025
- Nov 30, 2021
How other firms rate IOBT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Piper Sandler | Neutral | $0.50 | Jan 26, 2026 |
| Morgan Stanley | Underweight | $0.36 | Jan 8, 2026 |
Questions about Morgan Stanley and IOBT
- What is Morgan Stanley's price target for IOBT?
- Morgan Stanley's latest stated price target for IO Biotech Inc. (IOBT) is $0.36, from its action on Jan 8, 2026.
- What is Morgan Stanley's rating on IOBT?
- Morgan Stanley rates IOBT Underweight, a bearish rating, as of Jan 8, 2026.
- When did Morgan Stanley last change its view on IOBT?
- On Jan 8, 2026, Morgan Stanley downgrades to Underweight from Equal-Weight, price target $0.36.
All Morgan Stanley ratingsIOBT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.